. . . . . . . . . . . . "[As more health authorities approve targeted compounds in a variety of treatment lines, use of this approach is expected only to increase.Gefitinib, an oral tyrosine kinase inhibitor (tki), is approved by Health Canada in the first-line setting of advanced non-small-cell lung carcinoma (nsclc) for tumours that harbour the EGFR gene mutation.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en . . . . . "2015-02-21"^^ . . "Gene-disease associations manually curated."@en . "DisGeNET evidence - CURATED"@en . "2015-08-25T14:37:48+02:00"^^ . . . . . . . . . . . "v3.0.0.0" . "v3.0.0" .